“We are very interested in learning how we can best participate in the future of Regenerative Medicine (RM), which is one of the reasons we joined ARMI,” said Reginald Stilwell, Director of the AlloSource Innovation Center and Futurist, adding, “We have a large body of expertise to contribute in the cell and tissue areas, and we also want to learn as much as we can.”
AlloSource is a 501(c)3, not-for-profit organization, headquartered in Centennial, Colorado with approximately 500 employees dedicated to advancing the science and use of transplantable allogeneic cells and tissue through pioneering research in regenerative therapies.
“Here at AlloSource, we are very interested in finding and incorporating technologies that can synergistically work with the matrices and cells naturally available in allogeneic tissue. The company’s interest in regenerative medicine and the application of bioengineering principles has led to an increasing degree of expertise in being able to formulate, fabricate, and commercialize regenerative medicine products currently being used in various orthopedic and other surgical repair procedures,” explained Stilwell.
The organization offers life-saving and life-enhancing solutions in orthopedic, spine, soft-tissue, burn and wound procedures to help restore patient health and mobility through more than 200 types of precise bone, skin, and soft-tissue and cellular allografts.
As one of the largest tissue banks in the US, and the largest processor of human cellular allografts in the world, one of AlloSource’s most notable products is ProChondrix (living chondrocyte tissue to repair osteochondral defects). The company has a focus on human tissue processing, product development and commercialization, as well as regenerative medicine and tissue engineering partnerships.
AlloSource is a federally registered (FDA) human tissue bank for the processing of human musculoskeletal and other tissues for transplant and the company is experienced in the regulatory environment cited in guidelines for FDA product development requirements for Human Cell & Tissue Products (PHS 361 HCT/P), medical devices (510k, etc.) and biologic regenerative medicine products. AlloSource is accredited by the American Association of Tissue Banks.
Many AlloSource associates are scientifically trained and experienced in aspects of tissue engineering including biomechanics, cell biology, process chemistry, histopathology, analytical sciences as well as in vitro and in vivo modeling for demonstration of new product mechanism of action.
Stillwell cited seven key areas of interest for ARMI member collaboration:
Skin Regeneration, “Our primary interest in this area is developing regenerative products and manufacturing processes that enable the use of allograft-sourced tissue to produce skin products that are suitable for deep-partial thickness and full thickness burns;”
Bone & Cartilage Regeneration, “Our interest in this area is the development of manufacturing processes that enable the use of allograft-sourced tissues with demonstrated osteogenecity to be fabricated into osteoinductive materials in various forms. Likewise we are interested in regenerating the cartilage layer of osteochondral tissue;”
Muscle Regeneration, “In this area, our interest is in the development of manufacturing processes that allow allograft-sourced tissue or biomaterials such as membranes or decellularized tissue to be used in the fabrication of muscle units;”
Nerve Regeneration, “Our interest in this area is in the development of manufacturing processes that allow allograft-sourced tissue such as acellular matrices to be used in the manufacture of neural conduits;”
Nanotechnology, “Our interest here is using acellular tissue matrix to “guide” tissue regeneration by providing proper nano-architecture for cellular infiltration;”
Immunotherapy, “Using the immunomodulatory and anti-inflammatory properties of mesenchymal stem cells (MSC) to a greater therapeutic effect than currently seen - we are interested, with our MSC, in cryobiology for long term preservation of cells and tissues;” and
3-D Bioprinting- “While we recognize that bioprinting is in its infancy, AlloSource can provide expertise in tissue processing and aims to incorporate tissue-specific ECM, proteins and cells into novel and biologically-relevant bioinks.
“Our company brings substantial expertise in tissue engineering, product development, and commercialization that can complement the discovery work of academic researchers and other early stage investigators helping to turn ideas, discoveries, and bioengineering concepts into commercialized products for human implant to help patients heal. This is central to AlloSource’s mission of “honoring the gift of tissue donation,” and we hope to find collaboration opportunities among the great work taking place within ARMI’s membership,” concluded Stilwell.